Dial-in Number
| Web session
|
HL7 Antitrust Policy
Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).
Attendees
Name | Organization |
---|---|
Melva Peters (Chair) | Jenaker Consulting |
John Hatem | Independent Consultant |
Stephen Chu | ADHA |
Tim McNeil | Surescript |
Scott Robertson | Kaiser Permanente |
Jean Duteau | Duteau Design |
Joseph Quinn | Smile CDR |
Corey Spears | MITRE |
Christof Gessner | HL7 Germany |
Frank McKinney | POCP |
Agenda Items and Notes
Meeting Notes from previous meeting
- 2021-11-15 Agenda/Meeting Notes - Pharmacy - accepted by general consensus
Project Review
Project Proposals
Project Scope Statements
- Project Scope Statements
- International Patient Access - added a comment
Discussion of MedicationKnowledge changes (Jean Duteau)
- - no update
- have already taken in to account changes from BR&R
- don't use ingredient
- reference to MedicinalProductDefinition
- have already taken in to account changes from BR&R
Catalog Updates (John Hatem)
-
- targeting May 2022 ballot for next Catalog IG
- dependent on FMG to provide a plan for FHIR IGs in R5 - can create an IG against 4.6.0 but not current build
- working on JIRA issues for Device Definition
- targeting May 2022 ballot for next Catalog IG
Workflow Update (John Hatem)
- not meeting this week. Next meeting is November 29th
Healthcare Product Update (John Hatem)
- HCP meeting discussed Scope and Boundaries for the Biologically Derived Product resource. Pharmacy needs clarification I believe on what items will be ordered via the Biologically Derived Product Resource. The items that Pharmacy will need to focus on are:
- Need to determine if we will reference biologically derived product from our resources - if there is a chance that any biologically derived product could be ordered from Pharmacy, then our resources need to be updated to reference the resource.
- Pharmacy needs to review resources to determine what resources should be referenced - add a tracker
NCPDP Updates (NCPDP Members)
Consultant Pharmacist Consult Note Updated PSS - Scott and Shelly. See
-
PSS-1884Getting issue details...
STATUS
Scott will update and it will come back to Pharmacy for review
Global Supply Chain Project (Scott)
- heard back from Jose - will try to re-invigorate the project
Medication List Guidance project (John)
- - no updates this week
Projects
Pharmacy Templates
- waiting for requirements from Christof and then will decide on next steps for new version
- Still waiting for approval of change request in Europe
- additional elements to be added - part relationship
PDex Formulary (Corey)
- Approval of IG for ballot - vote November 29
FHIR (Group)
BR&R managed resources review
- no recent meetings
New Resource - FormularyItem
- January 21 - new resource proposal deadline for May 2022 ballot
Preparation for Normative
- Melva to work with John about QA needed
Trackers - link to pharmacy unresolved Jira trackers (see trackers for details / resolutions)
Any Other Business
- Medication List Project from EHR
- Reducing Clinician Burden Project in EHR - sub project around Medication Reconciliation processes
- have questions about what they are doing - EHR has not reached out to Pharmacy about this project
- have asked them to come and talk to us about this project
- Reducing Clinician Burden Project in EHR - sub project around Medication Reconciliation processes
Next meeting
- November 29, 2021
- Formulary IG approval to go to ballot
- EHR Medication Reconciliation
- Nutrition
- reach out to IPA team to have them come to an upcoming call to discuss medication related content